The World Health Organization has classified the current Ebola surge in the Democratic Republic of Congo as the most extensive in the country’s recorded history. Premium Times reported that 10,668 individuals tested positive for the disease, resulting in 5,198 fatalities by early November 2026. The infection has impacted 67 distinct health zones across eight provinces, with active transmission persisting in 51 of those areas. Ituri and North Kivu provinces bear the heaviest burden, containing the majority of both confirmed infections and deaths.
AllAfrica highlighted the absence of a dedicated licensed vaccine for the Bundibugyo strain, a virus first identified in Uganda in 2007. Torsten Feldt, a tropical medicine specialist at Düsseldorf's University Hospital, argued that earlier outbreaks in 2007 and 2012 offered sufficient time to prepare therapeutic options. Leonie Mayer, a researcher at the German Center for Infection Research, concurred that pre-clinical trials could have been initiated sooner. However, she noted that real-world effectiveness is often best verified during an active epidemic.
Mayer’s team recently investigated if Ervebo, a vaccine approved for the Zaire variant, generates immune responses against other Ebola types. Their findings indicated cross-reactive T-cell activity targeting the Bundibugyo virus. Mayer explained that this recognition does not guarantee protection or milder symptoms, leaving a significant knowledge gap. Jürgen May from the Bernhard Nocht Institute cautioned that deploying unproven vaccines widely might undermine public trust if results are mixed.
The Tumaini study, now active in Congo, is evaluating multiple vaccine candidates, including Ervebo and a Moderna mRNA formulation, to determine their specific efficacy against Bundibugyo. Experts suggest widespread availability may not arrive until mid-2027. Meanwhile, the WHO expressed concern about high community death rates, particularly among young children, which complicates early detection. Nigeria and Kenya continue monitoring their cases, with no new infections reported in either nation since late October 2026.